Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adagene Inc.
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
- Digital Health
- Drug Discovery Tools
- Other Names / Subsidiaries
- Adagene (Hong Kong) Limited
- Adagene (Suzhou) Limited
- Adagene (Suzhou China)
- Adagene Incorporated